

Per Eystein Lonning

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/6649799/publications.pdf>

Version: 2024-02-01

185
papers

37,102
citations

50276

46
h-index

4645

170
g-index

191
all docs

191
docs citations

191
times ranked

26900
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular portraits of human breast tumours. <i>Nature</i> , 2000, 406, 747-752.	27.8	13,397
2	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10869-10874.	7.1	9,721
3	Repeated observation of breast tumor subtypes in independent gene expression data sets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8418-8423.	7.1	4,849
4	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1081-1092.	27.0	1,694
5	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. <i>Nature Medicine</i> , 1996, 2, 811-814.	30.7	797
6	Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. <i>British Journal of Cancer</i> , 1996, 74, 1286-1291.	6.4	312
7	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 87-100.	10.7	307
8	Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 2234-2244.	1.6	302
9	Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5126-5137.	1.6	278
10	Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. <i>Cancer Research</i> , 2001, 61, 2505-12.	0.9	240
11	In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. <i>Clinical Cancer Research</i> , 1998, 4, 2089-93.	7.0	229
12	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 111-116.	2.5	219
13	Genetic variants of CYP19 (aromatase) and breast cancer risk. <i>Oncogene</i> , 2000, 19, 1329-1333.	5.9	153
14	Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. <i>Clinical Cancer Research</i> , 2008, 14, 6330-6335.	7.0	121
15	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 240-249.	1.2	115
16	Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer. <i>Drugs</i> , 1988, 35, 685-710.	10.9	96
17	Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. <i>The Journal of Steroid Biochemistry</i> , 1990, 35, 355-366.	1.1	93
18	Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. <i>European Journal of Cancer</i> , 2006, 42, 2968-2975.	2.8	92

#	ARTICLE	IF	CITATIONS
19	Intratumoral Estrogen Disposition in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1790-1801.	7.0	92
20	Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 117, 31-41.	2.5	89
21	NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. <i>Breast Cancer Research</i> , 2018, 20, 120.	5.0	85
22	Impact of <i>KRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> , <i>TP53</i> status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	5.1	79
23	The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. <i>British Journal of Cancer</i> , 1991, 63, 789-793.	6.4	77
24	Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. <i>Cancer Research</i> , 1992, 52, 4719-23.	0.9	77
25	Aromatase inhibitors in breast cancer.. <i>Endocrine-Related Cancer</i> , 2004, 11, 179-189.	3.1	76
26	CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. <i>PLoS ONE</i> , 2008, 3, e3062.	2.5	74
27	Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. <i>Cancer Research</i> , 1990, 50, 5851-7.	0.9	73
28	Accidental hypothermia Review of the literature. <i>Acta Anaesthesiologica Scandinavica</i> , 1986, 30, 601-613.	1.6	68
29	Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor and insulin-like growth factor binding protein in postmenopausal breast cancer patients. <i>Clinical Endocrinology</i> , 1995, 42, 23-30.	2.4	65
30	Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. <i>PLoS ONE</i> , 2011, 6, e19249.	2.5	65
31	Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer. <i>Clinical Pharmacokinetics</i> , 1992, 22, 327-358.	3.5	62
32	An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 109, 90-95.	2.5	62
33	Patterns of genomic evolution in advanced melanoma. <i>Nature Communications</i> , 2018, 9, 2665.	12.8	62
34	Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 52, 491-496.	2.5	61
35	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. <i>Clinical Cancer Research</i> , 2011, 17, 4948-4958.	7.0	58
36	Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R47.	5.0	58

#	ARTICLE	IF	CITATIONS
37	P53 and its molecular basis to chemoresistance in breast cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S23-S30.	3.4	57
38	The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology, 2011, 22, 503-514.	1.2	56
39	Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. British Journal of Cancer, 1989, 60, 107-111.	6.4	55
40	Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology, 2007, 18, 1293-1306.	1.2	55
41	Breast cancer prognostication and prediction: are we making progress?. Annals of Oncology, 2007, 18, viii3-viii7.	1.2	52
42	Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients. Clinical Pharmacokinetics, 1987, 13, 393-406.	3.5	51
43	Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. European Journal of Cancer, 2009, 45, 527-535.	2.8	51
44	A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 409-412.	2.5	47
45	Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 1996, 39, 335-341.	2.5	47
46	Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2003, 39, 438-446.	2.8	47
47	Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica, 2007, 46, 153-164.	1.8	47
48	Lapatinib in early breast cancer—questions to be resolved. Lancet Oncology, The, 2013, 14, 11-12.	10.7	46
49	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.7	46
50	Mechanisms of action of endocrine treatment in breast cancer. Critical Reviews in Oncology/Hematology, 1995, 21, 158-193.	4.4	45
51	Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine, 2012, 25, 1033-1042.	2.8	45
52	Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene, 2013, 32, 5315-5330.	5.9	44
53	Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment, 1998, 49, S45-S52.	2.5	41
54	Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology, 2006, 17, 217-225.	1.2	41

#	ARTICLE	IF	CITATIONS
55	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy, 2014, 15, 681-700.	1.8	41
56	Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer, 2009, 101, 1253-1260.	6.4	39
57	MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget, 2011, 2, 251-258.	1.8	39
58	RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Annals of Oncology, 2011, 22, 2208-2215.	1.2	38
59	Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. The Journal of Steroid Biochemistry, 1989, 32, 91-97.	1.1	37
60	Molecular basis for therapy resistance. Molecular Oncology, 2010, 4, 284-300.	4.6	37
61	White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. Annals of Internal Medicine, 2018, 168, 326.	3.9	37
62	Additive endocrine therapy for advanced breast cancer â€“ back to the future. Acta OncolÃ³gica, 2009, 48, 1092-1101.	1.8	36
63	Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. European Journal of Cancer, 2014, 50, 1055-1064.	2.8	35
64	Microarrays in primary breast cancer--lessons from chemotherapy studies.. Endocrine-Related Cancer, 2001, 8, 259-263.	3.1	34
65	Effects of the<i>MDM2</i>promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription, 2011, 2, 207-210.	3.1	34
66	Aromatase Inhibition for Breast Cancer Treatment. Acta OncolÃ³gica, 1996, 35, 38-43.	1.8	33
67	MDM4 SNP34091 (rs4245739) and its effect on breastâ€™ colonâ€™ lungâ€™, and prostate cancer risk. Cancer Medicine, 2015, 4, 1901-1907.	2.8	33
68	Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. Clinical Pharmacology and Therapeutics, 1984, 36, 796-802.	4.7	31
69	Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment, 1992, 23, 57-62.	2.5	30
70	Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology, 1991, 27, 367-372.	2.3	28
71	Recent data on intratumor estrogens in breast cancer. Steroids, 2011, 76, 786-791.	1.8	28
72	Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. The Journal of Steroid Biochemistry, 1989, 34, 551-553.	1.1	27

#	ARTICLE	IF	CITATIONS
73	Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. <i>Maturitas</i> , 1998, 28, 259-265.	2.4	27
74	Aromatase inhibitors in the treatment of early and advanced breast cancer. <i>Acta Oncol</i> ³ <i>gica</i> , 2005, 44, 23-31.	1.8	27
75	Influence of <i>MDM2</i> SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. <i>International Journal of Cancer</i> , 2015, 137, 96-103.	5.1	27
76	Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. <i>The Journal of Steroid Biochemistry</i> , 1989, 33, 541-545.	1.1	26
77	Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 241-244.	2.3	26
78	Impact of aromatase inhibitors on bone health in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 294-299.	2.5	26
79	Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 127-137.	3.2	26
80	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1580-1583.	1.6	26
81	Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-II, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996, 57, 167-171.	2.5	25
82	Pharmacology and clinical experience with exemestane. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1897-1905.	4.1	24
83	Pharmacokinetics and metabolism of formestane in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 77, 39-47.	2.5	23
84	Concomitant inactivation of the p53 and pRB functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. <i>Molecular Oncology</i> , 2015, 9, 1553-1564.	4.6	23
85	Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. <i>Journal of Endocrinology</i> , 1995, 146, 359-363.	2.6	22
86	Insulin-Like Growth Factors in Breast Cancer. <i>Acta Oncol</i> ³ <i>gica</i> , 1996, 35, 19-22.	1.8	22
87	Anastrozole – A New Generation in Aromatase Inhibition: Clinical Pharmacology. <i>Oncology</i> , 1997, 54, 11-14.	1.9	22
88	Exemestane: a review of its clinical efficacy and safety. <i>Breast</i> , 2001, 10, 198-208.	2.2	22
89	A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1155-1163.	2.8	22
90	Constitutional Mosaic Epimutations – a hidden cause of cancer?. <i>Cell Stress</i> , 2019, 3, 118-135.	3.2	22

#	ARTICLE	IF	CITATIONS
91	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). <i>Oncotarget</i> , 2014, 5, 8223-8234.	1.8	22
92	Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. <i>Oncotarget</i> , 2016, 7, 28637-28646.	1.8	22
93	Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. <i>The Journal of Steroid Biochemistry</i> , 1989, 33, 565-571.	1.1	21
94	Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 55, 193-195.	2.5	20
95	Aromatase Inhibitors and Inactivators for Breast Cancer Therapy. <i>Drugs and Aging</i> , 2002, 19, 277-298.	2.7	20
96	Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 108, 196-202.	2.5	20
97	Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1998, 78, 12-15.	6.4	19
98	Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow's Challenges. <i>Clinical Breast Cancer</i> , 2001, 1, 297-308.	2.4	19
99	Stepwise estrogen suppression manipulating the estrostat. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 79, 127-132.	2.5	19
100	Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 63, 53-58.	2.5	18
101	Bone safety of aromatase inhibitors versus tamoxifen. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 518-520.	2.5	18
102	Aromatase inhibitors as adjuvant treatment of breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 53-61.	4.4	18
103	Indications and limitations of third-generation aromatase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 723-739.	4.1	18
104	Determination of Warfarin in Human Plasma by High Performance Liquid Chromatography and Photodiode Array Detector. <i>Therapeutic Drug Monitoring</i> , 1985, 7, 329-335.	2.0	17
105	Systemic Therapy in Breast Cancer. <i>Pharmacoeconomics</i> , 1994, 5, 198-212.	3.3	17
106	Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment. <i>Acta Oncologica</i> , 1998, 37, 365-368.	1.8	17
107	Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators. <i>Clinical Pharmacokinetics</i> , 2003, 42, 619-631.	3.5	17
108	An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa047.	0.2	17

#	ARTICLE	IF	CITATIONS
109	Treatment of Breast Carcinoma with Aminoglutethimide. <i>Acta Radiologica Oncology</i> , 1984, 23, 421-424.	0.5	16
110	Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin. <i>The Journal of Steroid Biochemistry</i> , 1989, 33, 631-635.	1.1	16
111	Pharmacological and clinical profile of anastrozole. <i>Breast Cancer Research and Treatment</i> , 1998, 49, S53-S57.	2.5	16
112	Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 96, 415-422.	2.5	16
113	Mutations and polymorphisms of the p21B transcript in breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 908-910.	5.1	16
114	Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 237-241.	2.5	16
115	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 867-876.	3.3	16
116	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017, 8, 41227-41241.	1.8	16
117	C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. <i>Nature Communications</i> , 2022, 13, 69.	12.8	16
118	Treatment of breast cancer with aromatase inhibitors – current status and future prospects. <i>British Journal of Cancer</i> , 1989, 60, 5-8.	6.4	15
119	Cross-resistance to different aromatase inhibitors in breast cancer treatment.. <i>Endocrine-Related Cancer</i> , 1999, 6, 251-257.	3.1	15
120	Adjuvant Endocrine Treatment of Early Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 223-238.	2.2	15
121	Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 128, 69-75.	2.5	15
122	Determination of Aminoglutethimide and N-Acetylaminoglutethimide in Human Plasma by Reversed-Phase Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 1984, 6, 221-226.	2.0	14
123	Aromatase Inhibitors in Malignant Diseases of Aging. <i>Drugs and Aging</i> , 1992, 2, 530-545.	2.7	14
124	Clinico-pharmacological aspects of different hormone treatments. <i>European Journal of Cancer</i> , 2000, 36, 81-82.	2.8	14
125	TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. <i>Acta Oncologica</i> , 2014, 53, 1347-1355.	1.8	14
126	MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. <i>BMC Cancer</i> , 2017, 17, 97.	2.6	14

#	ARTICLE	IF	CITATIONS
127	Alterations of the retinoblastoma gene in metastatic breast cancer. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 319-326.	3.3	13
128	Estradiol measurement in translational studies of breast cancer. <i>Steroids</i> , 2015, 99, 26-31.	1.8	13
129	Determination of Droloxifene and Two Metabolites in Serum by High-Pressure Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 1995, 17, 259-265.	2.0	12
130	Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. <i>Cancer Letters</i> , 1999, 145, 73-77.	7.2	12
131	Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations. <i>Acta Oncologica</i> , 2007, 46, 199-203.	1.8	12
132	Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 288-293.	2.5	12
133	The multitude of molecular analyses in cancer: the opening of Pandora's box. <i>Genome Biology</i> , 2014, 15, 447.	8.8	12
134	New Endocrine Drugs for Treatment of Advanced Breast Cancer. <i>Acta Oncologica</i> , 1990, 29, 379-386.	1.8	11
135	Prognostic and predictive value of ER ⁺ and ER ⁺ in the Intergroup Exemestane Study (IES) – first results from PathIES. <i>Annals of Oncology</i> , 2015, 26, 1890-1897.	1.2	11
136	Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. <i>BMC Cell Biology</i> , 2017, 18, 17.	3.0	11
137	The role of aromatase inactivators in the treatment of breast cancer. <i>International Journal of Clinical Oncology</i> , 2002, 7, 265-270.	2.2	10
138	Treatment of Early Breast Cancer with Conservation of the Breast a Review. <i>Acta Oncologica</i> , 1991, 30, 779-792.	1.8	8
139	Effects of SNP variants in the 17 ^β -HSD2 and 17 ^β -HSD7 genes and 17 ^β -HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 192-198.	2.5	8
140	MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. <i>Scientific Reports</i> , 2016, 6, 33153.	3.3	8
141	Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 2163-2174.	0.9	8
142	Comparison between aromatase inhibitors and sequential use. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 275-282.	2.5	7
143	Strength and weakness of phase I to IV trials, with an emphasis on translational aspects. <i>Breast Cancer Research</i> , 2008, 10, S22.	5.0	7
144	Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. <i>Gene</i> , 2021, 793, 145747.	2.2	7

#	ARTICLE	IF	CITATIONS
145	Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 151-5.	2.5	7
146	Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice, 2016, 14, 19.	1.5	6
147	The potential for aromatase inhibition in breast cancer prevention. Clinical Cancer Research, 2001, 7, 4423s-4428s; discussion 4411s-4412s.	7.0	5
148	Dose Response Evaluation. Clinical Pharmacokinetics, 1993, 25, 1-5.	3.5	4
149	Exemestane in Breast Cancer: Current Status and Future Directions. Clinical Breast Cancer, 2000, 1, S28-S33.	2.4	4
150	Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?. Drugs, 2000, 60, 11-21.	10.9	4
151	Chemosensitivity and p53; new tricks by an old dog. Breast Cancer Research, 2012, 14, 325.	5.0	4
152	Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. Journal of Clinical Oncology, 2006, 24, 10532-10532.	1.6	4
153	Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 255-60.	2.5	4
154	Exemestane for breast cancer prevention: a feasible strategy?. Clinical Cancer Research, 2005, 11, 918s-24s.	7.0	4
155	Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients. Cancer Chemotherapy and Pharmacology, 1998, 42, 46-52.	2.3	3
156	Aromatase inhibitorsâ€”Socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 137-142.	2.5	3
157	The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-â†5 in Breast Cancer Cells. Translational Oncology, 2017, 10, 806-817.	3.7	3
158	Comment on “Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies” by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594. Lab on A Chip, 2017, 17, 3186-3187.	6.0	3
159	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Research and Treatment, 2018, 168, 169-178.	2.5	3
160	Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1368-1374.	3.6	3
161	Aromatase inhibitorsâ€”Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 55-61.	2.5	2
162	Tailored targeted therapy for all: a realistic and worthwhile objective?. Breast Cancer Research, 2009, 11, S7.	5.0	2

#	ARTICLE	IF	CITATIONS
163	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.. Journal of Clinical Oncology, 2022, 40, e13634-e13634.	1.6	2
164	Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews, 1993, 19, 65-77.	7.7	1
165	Paclitaxel and Docetaxel. Pharmacoeconomics, 1995, 8, 1-4.	3.3	1
166	P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. International Journal of Cancer, 2007, 120, 2749-2749.	5.1	1
167	Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?. Trends in Cancer, 2021, 7, 181-185.	7.4	1
168	Abstract 1878: Performance comparison of BRAF V600E detection assays in malignant melanoma and colorectal cancer specimens. , 2014, , .		1
169	Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology, 2013, 31, TPS650-TPS650.	1.6	1
170	Genomic heterogeneity in primary breast cancer: Clinical implications.. Journal of Clinical Oncology, 2014, 32, 11004-11004.	1.6	1
171	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 555-555.	1.6	1
172	Constitutional <i>BRCA1</i> methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 10509-10509.	1.6	1
173	The relation between cell proliferation and adenylate cyclase activity in grafts of 3-methylcholanthrene induced mouse uterine cervical tumors. Experientia, 1982, 38, 387-389.	1.2	0
174	Exemestane. Drugs, 1999, 58, 681-682.	10.9	0
175	Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Breast Cancer Online: BCO, 2006, 9, 1-3.	0.1	0
176	Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer?. Nature Clinical Practice Oncology, 2006, 3, 356-357.	4.3	0
177	EFFECT OF ESTRADIOL AND PROGESTERONE ON THE ADENYLATE CYCLASE ACTIVITY IN GRAFTS OF 3-METHYLCHOLANTHRENE INDUCED CARCINOMAS IN THE MOUSE UTERINE CERVIX. Acta Pathologica Et Microbiologica Scandinavica Section A, Pathology, 1980, 88A, 111-118.	0.1	0
178	Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports, 2009, 1, 183-189.	1.0	0
179	Are current development programs realising the full potential of new agents?. Breast Cancer Research, 2010, 12, S23.	5.0	0
180	Normal breast tissue estrogen levels. Maturitas, 2015, 81, 327.	2.4	0

#	ARTICLE	IF	CITATIONS
181	Comments on paper: "Quantitative determination of estrone by liquid chromatography-tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal women" by Vihma et al.. Journal of Steroid Biochemistry and Molecular Biology, 2016, 159, 72.	2.5	0
182	Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers. , 2010, , .		0
183	Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study. , 2012, , .		0
184	Abstract 863: Tyrosine kinase activity profiling of metastatic malignant melanoma: Identification of possible therapeutic targets and markers predicting response to therapy. , 2012, , .		0
185	Abstract 3139: Identification and functional studies of p53 mutants detected in breast cancers after chemotherapy treatment.. , 2013, , .		0